Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins

Abstract

BackgroundLipopolysaccharide (LPS), also referred to as endotoxin, is the major constituent of the outer leaflet of the outer membrane of virtually all Gram-negative bacteria. The lipid A moiety, which anchors the LPS molecule to the outer membrane, acts as a potent agonist for Toll-like receptor 4/myeloid differentiation factor 2-mediated pro-inflammatory activity in mammals and, thus, represents the endotoxic principle of LPS. Recombinant proteins, commonly manufactured in Escherichia coli, are generally contaminated with endotoxin. Removal of bacterial endotoxin from recombinant therapeutic proteins is a challenging and expensive process that has been necessary to ensure the safety of the final product.ResultsAs an alternative strategy for common endotoxin removal methods, we have developed a series of E. coli strains that are able to grow and express recombinant proteins with the endotoxin precursor lipid IVA as the only LPS-related molecule in their outer membranes. Lipid IVA does not trigger an endotoxic response in humans typical of bacterial LPS chemotypes. Hence the engineered cells themselves, and the purified proteins expressed within these cells display extremely low endotoxin levels.ConclusionsThis paper describes the preparation and characterization of endotoxin-free E. coli strains, and demonstrates the direct production of recombinant proteins with negligible endotoxin contamination.Electronic supplementary materialThe online version of this article (doi:10.1186/s12934-015-0241-5) contains supplementary material, which is available to authorized users.

Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles

“…In this context, and to examine in detail the potential intrinsic heterogeneity in the architecture of these materials, we have screened by SEC the intra-strain size spectrum of T22-GFP-H6 nanoparticles occurring in these two separate IMAC fractions, upon production in different E. coli strains. We included in the analysis the endotoxin-free E. coli strain KPM335, that is particularly interesting not only because of its interest in biomedicine as an endotoxin-free cell factory [29] but also because of the complex genetic modifications performed to remove endotoxic components from the cell wall. Such manipulation has resulted in the constitutive up or down regulation of several heat-shock genes involved in the quality control of recombinant proteins [23].…”

Bacterial Inclusion Bodies: Discovering Their Better Half

“…The controlled production of functional IB analogues in Pichia pastoris [88] and in the food-grade bacterium Lactococcus lactis has just been demonstrated [89]. Together with the recent description of IB fabrication in endotoxin-free E. coli [90,91], the production of IBs in microorganisms other than Gram-negative, endotoxin-containing bacteria is expanding the catalogues of cell factories for biologically safer IB-related products, what would conduct to a smoother implementation of IB-based protein delivery technologies in different fields.…”

Biosynthesis and structure–activity relationships of the lipid a family of glycolipids

“…While considerable effort has been directed to investigate their structure-activity relationships, many of these studies go back to the early days of discovery of these biological pathways, and have therefore not taken sufficient advantage of more recent insights into Lipid A chemistry and biosynthesis. Meanwhile, a number of recent studies involving mutant [51,52] or engineered [9,53,54] Gram-negative bacteria have vividly demonstrated the potential for discovery of novel immune-modulatory agents via engineered biosynthesis and semisynthesis. The stage is set for the development of more advanced chemical biology platforms that exploit the resurgence of interest into the biology of one of nature's oldest and most powerful natural products.…”